5 May 2017 in Bioconjugate Chemistry
Engineering modular platforms to control biomolecular architecture can advance both the understanding and the manipulation of biological systems. Icosahedral particles uniformly displaying single antigens stimulate potent immune activation and have been successful in various licensed vaccines. However, it remains challenging to display multiple antigens on a single particle and to induce broader immunity protective across strains or even against distinct diseases. Here, we design a dually addressable synthetic nanoparticle by engineering the multimerizing coiled-coil IMX313 and two orthogonally reactive split proteins. SpyCatcher protein forms an isopeptide bond with SpyTag peptide through spontaneous amidation. SnoopCatcher forms an isopeptide bond with SnoopTag peptide through transamidation. SpyCatcher–IMX–SnoopCatcher provides a modular platform, whereby SpyTag–antigen and SnoopTag–antigen can be multimerized on opposite faces of the particle simply upon mixing. We demonstrate efficient derivatization of the platform with model proteins and complex pathogen-derived antigens. SpyCatcher–IMX–SnoopCatcher was expressed in Escherichia coli and was resilient to lyophilization or extreme temperatures. For the next generation of malaria vaccines, blocking the transmission of the parasite from human to mosquito is an important goal. SpyCatcher–IMX–SnoopCatcher multimerization of the leading transmission-blocking antigens Pfs25 and Pfs28 greatly enhanced the antibody response to both antigens in comparison to the monomeric proteins. This dual plug-and-display architecture should help to accelerate vaccine development for malaria and other diseases.
14 February 2018 in Journal of the American Chemical Society
15 March 2019 in Scientific Reports
AAAnne-Marie C. Andersson
For many infectious diseases there is still no vaccine, even though potential protective antigens have been identified. Suitable platforms and conjugation routes are urgently needed to convert the promise of such antigens into broadly protective and scalable vaccines. Here we apply a newly established peptide-peptide ligation approach, SnoopLigase, for specific and irreversible coupling of antigens onto an oligomerization platform. SnoopLigase was engineered from a Streptococcus pneumoniae adhesin and enables isopeptide bond formation between two peptide tags: DogTag and SnoopTagJr. We expressed in bacteria DogTag linked to the self-assembling coiled-coil nanoparticle IMX313. This platform was stable over months at 37 °C when lyophilized, remaining reactive even after boiling. IMX-DogTag was efficiently coupled to two blood-stage malarial proteins (from PfEMP1 or CyRPA), with SnoopTagJr fused at the N- or C-terminus. We also showed SnoopLigase-mediated coupling of a telomerase peptide relevant to cancer immunotherapy. SnoopLigase-mediated nanoassembly enhanced the antibody response to both malaria antigens in a prime-boost model. Including or depleting SnoopLigase from the conjugate had little effect on the antibody response to the malarial antigens. SnoopLigase decoration represents a promising and accessible strategy for modular plug-and-display vaccine assembly, as well as providing opportunities for robust nanoconstruction in synthetic biology.
17 July 2025 in Journal of Biological Chemistry
T-cell engaging antibodies (TCBs) have significant clinical potential; however, their application can be limited by a narrow therapeutic window. TCB prodrugs (proTCBs) that become preferentially activated at tumors may mitigate safety risks. Our previously published prodrug-activating chain exchange (PACE) approach utilized two inactive antibody derivatives that, upon coaccumulation on tumor cells, undergo chain-exchange reactions to reconstitute active CD3 binders. Here, we present a second-generation PACE approach. We refined the PACE prodrugs by including Fc domains to improve pharmacokinetic properties, and placed the conditional effector domain into linker-connected single-chain Fab (scFab) arms. These scFab-PACE prodrugs harbor a tumor-targeting arm and an inactive scFab effector arm composed of an Fd region and light chain from two separate binders. The Fd/light chain interface of the scFab harbors repulsive charges which triggers chain-exchange and binder activation upon accumulation on target cells. The scFab linker minimizes in-solution chain exchange, which reduces the risk of nonspecific prodrug activation. We demonstrate the feasibility of this approach for the generation of proTCBs using HER2-targeting scFab-PACE precursors with a CD3 binder prodrug as the effector. These prodrugs gain CD3-binding functionality upon accumulation on tumor cells in a HER2-density-dependent manner. ScFab-PACE also enables the combination of dual prodrug functionalities. We demonstrate this feature by generating prodrugs that conditionally engage both CD3 and CD28, allowing for target-specific simultaneous activation of T cell signal 1 and signal 2.